Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6754869 | 0.99 | ADORA2A (0.68) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Hydrochloric Acid SCHEMBL2031971 | 0.99 | ADORA2A (0.67) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL2295172 | 0.93 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL1976908 | 0.91 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL724837 | 0.91 | ADORA2A (0.58) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL940189 | 0.89 | ADORA2A (0.55) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Hydrochloric Acid SCHEMBL9247444 | 0.89 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL22533842 | 0.85 | ADORA2A (0.72) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Hydrochloric Acid SCHEMBL23859924 | 0.85 | ADORA2A (0.71) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| SCHEMBL5490949 | 0.82 | ADORA2A (0.73) | ADORA2AADORA3ADORA1ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | claimed |
| EP-2204154-A1 | Association of monosaccharides and adenosine and its cosmetic use | L'OREAL (FR) | 2010-07-07 | — | — | EP | claimed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | claimed |
| US-20070232560-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2007-10-04 | — | — | US | claimed |
| EP-1424064-B1 | Use of adenosin or an adenosin analog to smooth out fine lines | OREAL (FR) | 2007-06-06 | — | — | EP | claimed |
| WO-2007042679-A2 | COSMETIC COMPOSITION CONTAINING A NON-PHOSPHATE COMPOUND BASED ON ADENOSINE AND A TIGHTENING POLYMER | L'OREAL (FR) | 2007-04-19 | — | — | WO | claimed |
| US-20060240056-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2006-10-26 | — | — | US | claimed |
| US-20060099568-A1 | Signals and molecular species involved in senescence | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2006-05-11 | — | — | US | claimed |
| EP-1014995-A4 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | ADERIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | claimed |
| JP-2002505687-A | — | — | 2002-02-19 | — | — | JP | claimed |
| EP-0589964-B1 | METHOD AND COMPOSITION TO REDUCE MYOCARDIAL REPERFUSION INJURY | UNIV VANDERBILT (US) | 2001-12-12 | — | — | EP | claimed |
| EP-0880353-A4 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS INC (US) | 2001-04-18 | — | — | EP | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| US-5998423-A | IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST | THERASYS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| EP-0880353-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | Therasys, Inc. (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1998015276-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS, INC. (US) | 1998-04-16 | — | — | WO | claimed |
| US-5424297-A | Adenosine dextran conjugates | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1995-06-13 | — | — | US | claimed |
| US-5206222-A | Coadministering adenosine or an analog and lidocaine | VANDERBILT UNIVERSITY (US) | 1993-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.